Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors
19. September 2024 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of...
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
24. Juni 2024 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland
12. Juni 2024 05:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic
27. Mai 2024 05:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic Lugano...
Helsinn closes financing agreement with BancaStato to support business objectives and growth
10. Oktober 2023 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...
Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
12. Juni 2023 09:00 ET
|
Helsinn Healthcare S.A.
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
03. Februar 2023 08:00 ET
|
Helsinn
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 - Helsinn Group (“Helsinn”), a fully integrated...
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets
24. Januar 2023 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023 –...
Helsinn closes financing agreement with Oberland Capital
10. Januar 2023 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare disease products through in-licensing or acquisitionDr...
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
09. Januar 2023 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer - Giorgio Calderari appointed Vice Chairman of the Board Lugano, Switzerland, January 9, 2023 - Helsinn Group...